Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
日曜日, 8 23

Foghorn Therapeutics Inc

FHTXNASDAQ
Trade with Public
Trade with Public
$7.07
0.060.86%
近くで: Aug 21, 5:00 PM EST
$7.09
0.020.28%
時間外: Aug 21, 7:55 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Foghorn Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Foghorn Therapeutics (FHTX).

Price Target Range — 9 Quarters

Analyst Consensus — 9 Analysts

1S.Buy
8Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$12Upside to Avg. PT+71.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 12, 2026WedbushRobert DriscollMaintainedOutperform$10
Mar 10, 2026HC Wainwright & Co.Andres Y. MaldonadoMaintainedBuy$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
Benzinga Newsdesk

PRO
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11

BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12

Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Avi Kapoor

PRO
Guggenheim Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12

Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved